Increased clinical and economic advantage of proteinuric screening and intervention (PROSIT project) in type 2 diabetics;Erhohter klinischer und wirtschaftlicher nutzen durch prosit (proteinurie screening und intervention) bei typ 2 diabetischen patienten

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 39, 2000, Pages 1154-1159

  Gozzoli, V ^a   Palmer, A J ^a   Brandt, A ^a   Weiss, Chr ^a   Piehlmeier, W ^b   Landgraf, R ^b   Renner, R ^c  

^a Institut für Medizininformatik und Biostatistik   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Chirurgische Klinik Munchen Bogenhausen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; SCREENING; ALBUMINURIA; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; HEALTH CARE COST; MASS SCREENING; SOCIOECONOMICS; STATISTICAL MODEL;

ALBUMINURIA; BLOOD PRESSURE; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GERMANY; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; LIPIDS; MASS SCREENING; MODELS, ECONOMIC; VALUE OF LIFE;

EID: 0034730252     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-7670     Document Type: Article

References (38)

1. Diabetes care and research in Europe
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Resource utilization and costs of care in the diabetes control and complications trial
4. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
5. Chronische niereninsuffizienz
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
7. Preventing diabetic nephropathy: The role of primary care
8. An updated coronary risk profile. A statement for health professionals
9. ACE-Hemmer und angiotensin-rezeptorantagonisten
10. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?
11. Eine klinische okonomische analyse alternativer behandlungsstrategien bei diabetischer nephropathie
12. Das diabetische fusssyndrom und seine risiken: Amputation, behinderung, hohe folgekosten
13. Staged diabetes management: Computerizing a disease state management program
14. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors
15. Soziookonornische evaluation am beispiel der nieren- und lebertransplantation
16. Ambulante versorgung von diabetikern - Eine analyse yon krankenkassendaten der AOK Dortmund
17. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals
18. Risk of hypoglycemia in users of human insulin. The Wisconsin Epidemiologic study of Diabetic Retinopathy
19. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
20. Screening diabetischer komplikationen - Prosit Projekt
21. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
22. Time preference
23. The cost-effectiveness of different management strategies for type 1 diabetes: A Swiss perspective
24. Evaluation of the Micral-Test S, a qualitative immunologic patient self- test for microalbuminuria: The PROSIT project, Proteinuria Screening and Intervention
25. Screening of diabetic patients for microalbuminuria in primary care - The PROSIT-Project. Proteinuria Screening and Intervention
26. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
27. Diabetic nephropathy in type II diabetes
28. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group
29. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care
30. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus
31. Pharmakookonomische bewertung yon pravastatin in der sekundarpravention der koronaren herzkrankheit bei patienten mit durchschnittlichen cholesterinwerten. Eine analyse for deutschland auf der grundlage der CARE-Studie
32. Kosten der intensivierten insulin-therapie bei diabetes mellitus Typ 1. Erfahrungen aus der DCCT-Studie
33. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group
34. Probability of stroke: A risk profile from the Framingham Study
35. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus